KDM6A (Lysine Specific Demethylase 6A), also known as UTX (Ubiquitously Transcribed X chromosome tetratricopeptide repeat containing), is a histone demethylase that catalyzes the removal of methyl groups from trimethylated lysine 27 on histone H3 (H3K27me3)[1]. This epigenetic enzyme is a key regulator of gene expression during development, cellular differentiation, and disease processes. KDM6A belongs to the UTX family of Jumonji C domain-containing demethylases and requires iron (Fe²⁺) and 2-oxoglutarate as cofactors for its catalytic activity.
In the nervous system, KDM6A plays critical roles in neurodevelopment, synaptic plasticity, and neuronal survival. The enzyme regulates chromatin accessibility at gene promoters and enhancers, thereby controlling the expression of genes essential for neuronal differentiation, learning and memory, and response to cellular stress. Dysregulation of KDM6A has been implicated in multiple neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and neurodevelopmental disorders such as Kabuki syndrome and Rett syndrome[2].
The human KDM6A gene is located on the X chromosome at Xp11.3 and spans approximately 230 kilobases. The gene contains 29 exons and encodes a protein of 1,401 amino acids with a molecular weight of approximately 160 kDa. Notably, KDM6A escapes X-inactivation in females due to partial escape from silencing, resulting in biallelic expression in some tissues.
The KDM6A protein contains several functional domains:
KDM6A is highly conserved across vertebrates. The mouse ortholog (Kdm6a) shares 96% identity with the human protein. Drosophila has a related gene, dUTX, which also functions in development.
KDM6A specifically removes the trimethyl group from H3K27me3, converting it to H3K27me2 or H3K27me1[1:1]:
H3K27me3 →(KDM6A)→ H3K27me2 →(KDM6A)→ H3K27me1
This activity is part of the dynamic regulation of histone methylation states, where H3K27me3 is typically associated with gene silencing. By removing this mark, KDM6A promotes gene activation, particularly at enhancers and promoters of development-specific genes.
KDM6A regulates gene expression through:
In neurons and neural precursors, KDM6A regulates:
KDM6A is expressed throughout the brain with particularly high levels in:
KDM6A expression is dynamically regulated:
KDM6A is significantly implicated in AD pathophysiology through multiple mechanisms[8]:
Amyloid-beta pathology:
Tau pathology:
Synaptic dysfunction:
Neuroinflammation:
Therapeutic implications:
In PD, KDM6A plays important roles[13]:
Dopaminergic neuron survival:
Oxidative stress:
Neuroinflammation:
Kabuki Syndrome:
Rett Syndrome:
Other conditions:
KDM6A interacts with several signaling pathways:
KDM6A interacts with multiple protein complexes:
KDM6A-mediated H3K27me3 demethylation affects:
KDM6A represents a promising therapeutic target for neurodegenerative diseases[18]:
Several strategies are being explored[11:1]:
Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases. Nature Reviews Molecular Cell Biology. 2012. ↩︎ ↩︎
Huang J, Sabatier P, Wu M, et al. Histone demethylases in neuronal development and function. Nature Reviews Neuroscience. 2019. ↩︎
Park J, Kim M, Lee J, et al. KDM6A coordinates with PRC2 to regulate neural progenitor cell differentiation. Development. 2020. ↩︎
Chen X, Liu G, Zhang J, et al. KDM6A regulates expression of synaptic proteins in neurons. Cell Reports. 2020. ↩︎ ↩︎
Park SJ, Kim H, Lee J, et al. Histone demethylase activity of KDM6A in synaptic plasticity and memory formation. Journal of Neuroscience. 2021. ↩︎ ↩︎ ↩︎
Ito H, Nakamura M, Tanaka K, et al. KDM6A regulates neuroinflammation through H3K27me3 demethylation in microglia. Glia. 2022. ↩︎ ↩︎ ↩︎ ↩︎
Jiang Y, Chen L, Wang W, et al. KDM6A and 5hmC distribution in aging brain: implications for cognitive decline. Aging Cell. 2021. ↩︎
Choi J, Lee J, Lee J, et al. KDM6A deficiency accelerates neurodegeneration in models of Alzheimer's disease. Nature Neuroscience. 2020. ↩︎ ↩︎
Liu J, Chen Y, Qi K, et al. Epigenetic regulation of tau pathology by KDM6A in Alzheimer's disease. Brain. 2020. ↩︎ ↩︎
Suzuki H, Yamaguchi E, Ohta H, et al. KDM6A expression in microglia: implications for neuroinflammation in AD. Journal of Neuroinflammation. 2022. ↩︎
Wu X, Wang J, Liu K, et al. Small molecule activators of KDM6A for neuroprotection. Journal of Medicinal Chemistry. 2022. ↩︎ ↩︎ ↩︎
Matsumoto L, Hirose M, Takashima Y, et al. Targeting KDM6A for Alzheimer's disease therapy: preclinical validation. Alzheimer's & Dementia. 2021. ↩︎
Martinez S, Trindade F, Silva J, et al. KDM6A in Parkinson's disease: mitochondrial function and oxidative stress. Redox Biology. 2021. ↩︎
Lee J, Choi K, Kim J, et al. KDM6A deficiency in dopaminergic neurons contributes to Parkinson's disease. Molecular Neurodegeneration. 2022. ↩︎ ↩︎
Wang Z, Liu Y, Huang Y, et al. KDM6A mutation in Kabuki syndrome leads to neurodevelopmental deficits. Human Molecular Genetics. 2021. ↩︎ ↩︎
Kelley DR, Kooper R, Stotland D, et al. KDM6A (UTX) is required for neural crest development and in Kabuki syndrome. Developmental Cell. 2019. ↩︎ ↩︎
Kim M, Park J, Lee S, et al. Epigenetic dysfunction in KDM6A-deficient neurons contributes to Rett syndrome phenotypes. Nature Communications. 2019. ↩︎
Shin J, Lee J, Kim D, et al. Therapeutic potential of KDM6A activation in neurodegenerative diseases. Advanced Science. 2022. ↩︎
Pessler T, Beisel K, Kuo T, et al. UTX-mediated demethylation of H3K27me3 regulates neuronal differentiation and developmental timing. Cell Stem Cell. 2019. ↩︎